CI
TGTX icon

Cordant Inc’s TG Therapeutics TGTX Stock Holding History

Cordant Inc’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,590
Closed -$102K – 104
2025
Q1 		$102K Buy
+2,590
New +$87.1K 0.05% 41
2021
Q4 		– Sell
-1,200
Closed -$40K – 334
2021
Q3 		$40K Buy
+1,200
New +$37.1K 0.02% 69

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cordant Inc's TGTX Position: Q2 2025 in Review

Cordant Inc sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 2,590 shares — an estimated $102K sold.

Cordant Inc first reported a position in TGTX in Q3 2021 and held it in 2 quarters. The position peaked at $102K in Q1 2025. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • Cordant Inc reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cordant Inc sold 2,590 TG Therapeutics shares in Q2 2025, an estimated $102K.
  • Cordant Inc first reported a position in TG Therapeutics in Q3 2021 and held it in 2 quarters.
  • Cordant Inc's TG Therapeutics position peaked at $102K in Q1 2025.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Cordant Inc's 13F filing for Q2 2025, filed 15 Jul 2025.